Rigor Reviewed

Rigor-Reviewed Manuscript

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.

Name: Αlpha¹ Rigor Record — Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.
Item: Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.
Rating: 100
Author: Αlpha¹

Basch E, Schrag D, Jansen J, Henson S, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak L, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Wolf AP, Dueck AC

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4★ (Strong), 0 critical, 2 high issues for “Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced2 types

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported multicenter cluster-randomized trial. The methods are rigorous, with clear randomization, power analysis, and prespecified criteria, and the reporting is thorough with trial registration, data availability, and limitations discussed. Minor reporting gaps include lack of explicit blinding rationale, outlier handling, and a Declaration of Helsinki statement, plus a few copyedit issues.

Both reviewers independently scored all eight dimensions as pass, with high agreement. The study is an interventional cluster-randomized trial; no divergence in study type. Non-applicable criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only 2 tests due to limited machine-verifiable statistics; the rest were not independently recomputed.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Reporting

Eight Dimensions8 pass

The introduction cites multiple prior trials and observational studies (STAR, CAPRI, Canadian population-based study) and discusses their strengths and limitations. The rationale for the trial is clearly linked to the objective of evaluating PRO symptom monitoring in a national US community oncology setting. The paper also addresses limitations of prior research, such as the single-center nature of STAR and the need for a multicenter trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise with extensive prior work cited, a logical rationale, and acknowledgment of prior limitations.

Evidence

paraphrase[Introduction, paragraph 2]

“Prior prospective trials and observational studies have reported benefits of implementing such electronic PRO symptom monitoring systems on quality of life outcomes, emergency department and hospital utilization and in some cases survival among patients receiving cancer treatment.”

paraphrase[Introduction, paragraph 3]

“To complement this body of evidence with a national trial in the United States, and modeled on the approach used in the STAR study, a multicenter cluster-randomized trial, PRO-TECT (Alliance AFT-39; NCT03249090), was designed and conducted in 52 community oncology practices to evaluate the real-world impact of electronic PRO symptom monitoring on clinical outcomes compared to usual care.”

paraphrase[Introduction, paragraph 3]

“A Canadian population-based observational study among more than 128,000 patients with cancer who either participated or did not participate in PRO symptom monitoring similarly found a statistically significant 8% reduction in emergency visits and a 14% reduction in hospitalizations associated with PRO.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale for the trial.

Evidence

paraphrase[Introduction, paragraph 2]

paraphrase[Introduction, paragraph 3]

direct quote[Discussion, paragraph 4]

“This trial has several limitations. Benefits may not have been experienced by all patients, and future research could aim to identify if certain subpopulations may particularly benefit.”